I. Physiology and biochemistry of androgens During development, from early fetal life through to adulthood, there are considerable changes in the levels of testosterone and other androgens. In order to appreciate the pathophysiological processes leading to disorders of androgen production and action it is necessary to have a good understanding of sexual differentiation, androgen biosynthesis and the physiology of androgen action.
SEXUAL DIFFERENTIATION (i) Genetic sex
Genetic sex is determined at the moment of fertilisation, a 46XX complement being necessary for normal human ovarian development and 46XY for normal human testicular development; chromosomal errors are caused by numerical or structural changes at the meiotic stage (i.e. sperm or ovum), or after fertilisation during mitosis in early embryological development.
(ii) Gonadal sex This is determined by the genetic sex. In the male, a gene present in the short arm of the Y chromosome is involved in the formation of a male-specific cell-surface H-Y (histocompatibility Y) antigen. Genes present on the X chromosome and possibly an autosome are also involved, but the exact site of the structural gene coding for the H-Y antigen is not known. 1-3 However, there is good evidence to suggest that This paper was prepared by a Task Force (Chairman, Dr A A A Ismail) at the invitation of the Analytical Methods Working Party of the Scientific Committee of the Association of Clinical Biochemists but docs not necessarily reflect the views of the Scientific Committee. Correspondence: Dr A A A Ismail. the expression of the H-Y antigen mediates the differentiation of the bipotential gonad into a testis. I, 2 Seminiferous tubules appear at about 7 weeks of gestation and Leydig cells become evident at about 8 weeks. 3. 4 In the absence of a Y chromosome, a fetal ovary usually develops, 1 although a number of cases of 46XX males have been described who were H-Y positive and who presented with hypogonadism in adult Iite.:' Assay for H-Y antigen is not yet routinely available.
(iii) Phenotypic sex Just as the primitive gonad will automatically develop into an ovary in the absence of a Y chromosome (H-Y antigen), so the work of Jost has shown that the internal and external genitalia will automatically develop along female lines in the absence of a testis.v" Thus, if the testes are removed before the critical period of development, at around 8 weeks of gestation, the Mullerian ducts develop into the fallopian tubes, uterus and upper vagina, and the Wolffian ducts degenerate. The external anlage also automatically differentiates into the clitoris, labia and lower vagina." However, when a testis is present, testicular secretion of two substances directs differentiation along male lines. A glycoprotein, anti-Mullerian hormone, secreted by Sertoli cells before 8 weeks gestation, induces degeneration of the Mullerian ducts. I. 4 Testosterone secretion stabilises the Wolffian ducts and promotes differentiation into the epididymis, vas deferens and seminal vesicle.:': 7. x Testosterone acts directly in these tissues as 5 a-reductase is not present at this time in development." However, the differentiation of the genitalia into penis, scrotum, prostate, etc., is dependent on intracellular 5 Ismail et at. a-reductase activity to convert secreted testosterone into 5 a-DHT, which is the intracellular mediator in these tissues.": K
TESTOSTERONE-BIOSYNTHESIS AND PHYSIOLOGY
The major synthetic pathways of testosterone are outlined in Fig. 1 . The hormone circulates in the serum bound to proteins, predominantly by binding to sex-hormone-binding globulin (SHBG).9 This is synthesised in the liver and has a molecular mass of approximately 100 000. The binding affinity of testosterone to SHBG at 37°C is one or two orders of magnitude less than that to the intracellular receptor protein. SHBG levels are themselves influenced by natural and synthetic sex hormones. Thus elevated plasma oestrogen concentrations (following administration or during pregnancy) may increase SHBG levels several times, whereas elevated testosterone can halve them. Other factors which may elevate SHBG are thyroid hormone excess'": 11 and cirrhosis of the liver." The testosterone remaining unbound, i.e. the free hormone, although only 1-3% of the whole, is the biologically active fraction. This exerts its androgenic action in target tissues largely by binding to the specific cytoplasmic receptors either directly or after conversion to 5 a-DHT via 5 a-reductase. The steroid receptor complex then travels to the nucleus to effect gene transcription. At the hypothalamic-pituitary level negative feedback occurs either via 5 a-reduction or aromatisation to oestradiol and binding to specific receptors.
In healthy men most of the circulating testosterone is derived from direct secretion by the testis (> 90%). The hormone concentration adequately reflects androgen status in the adult male, since other circulating androgens, though present in comparable or even greater concentration, are biologically weak. In healthy women, however, the circulating testosterone level is much lower (about one-tenth of that in men). Of this, 25% is derived from direct ovarian secretion and 25% from the adrenal cortex, but peripheral conversion of biologically weak androgens accounts for 50% or more of the total androgenic action in the female. 12 These weak androgens, therefore, merit consideration because of their involvement with testosterone action and production. The adrenals are the major source of dehydroepiandrosterone (DHA) and DHA-sulphate (DHA-S) and to a lesser extent androstenedione. Androgens directly secreted from the adrenal exhibit considerable diurnal variation in output with DHA-S showing the least pronounced rhythm. Although DHA and DHA-S are biologically weak androgens, they serve as precursors of the more potent androgen androstenediol and, to a lesser extent, testosterone. In healthy women, the plasma levels of testosterone do not fluctuate by more than ±20% during the day.
Testosterone is metabolised in the liver and the end-products form part of the 17-oxosteroid group. Most of the 17-oxosteroids in women, and to a lesser extent in men, are derived from weak adrenal androgens, i.e. DHA and androstenedione. Urinary 17-oxosteroids, therefore, reflect total androgen production, but the measurement is of no value in assessing testosterone production in either sex. I)
SERUM TESTOSTERONE LEVELS (i) Neonatal
During the neonatal period there is transient activation of the pituitary-gonadal axis in both sexes. In male infants, there is an increase in plasma testosterone on the first day of life which may reach a low adult level. 14. 15 This is presumably due to decreased clearance of testosterone after separation of the placenta plus continued stimulation of secretion by residual hCG . 16 By the end of the first week, this stimulus has been removed and the testosterone levels have fallen, and become similar in both sexes. During the second week of life, in both male and female infants there is a rise in plasma gonadotrophins, which is maintained much longer in girls. 16 In male infants, gonadotrophins peak at about one month of age and changes which parallel those of cortisol. 24 LH concentrations fluctuate in pubertal boys and men but plasma FSH levels remain more constant.F In normally menstruating women plasma testosterone levels fluctuate throughout the cycle, with highest levels at mid-cycle.P: 26 Normal adult testosterone levels are 0·5-2·5 nrnol/L in women and 10-30 nmol/L in men.
During childhood, circulating levels of gonadal steroids and gonadotrophins are very low, but it should be noted that the prepubertal testis is relatively more responsive to hCG stimulation than in the adult. I\). 211 The earliest endocrine event detected in maturing children is probably an increase in adrenal androgens, the so-called 'adrenarche'i ": 21 At the onset of puberty, pulsatile increases of gonadrotrophins occur which are initially seen only during sleep.": 22 As puberty progresses, these pulses increase in frequency and also occur during the day. In boys, testosterone secretion follows a similar pattern consequent upon LH stimulation ot'the testis and significant increases in serum testosterone occur, usually between 12 and 14 years of age (pubertal stage 3 to 4) ( Table 2 ). In girls, plasma testosterone concentration increases slowly throughout puberty ( Table 2 ).21. 2J decline to prepubertal levels by approximately four rnonths.!" As a consequence, the plasma testosterone concentration in male infants may rise to low normal adult levels during the second or third month of life before falling to prepubertal levels by six months of age. 1h -1K There are no significant increases in plasma testosterone in normal female infants (Table  i) .": 17 Results (nrnol/L) are expressed as median with the range in parentheses.
(iii) Adult
In adult men, testosterone secretion is episodic so that plasma levels are variable. There is also a circadian rhythm, with the highest levels seen early in the morning and the lowest in the evening.P The morning levels are approximately 20-40% higher than those in the evening. This is a much smaller change than for adrenocortical hormones and other androngens or their precursors that are of adrenal origin, i.e. androstenedione, DHA and 17-hydroxyprogesterone (17-0HP), which show circadian Age 1 day 1 week 1--4 months 4--12 months 1-2 years Male subjects
Female subjects 1·6 (0,7-2,7) 0·5 (1J.17-1·21) 0·24 (0,14),7) 0·21 (O·I-D· 7) 0·21 (0·1-D·7) INTRODUCTION The clinical presentation of disorders of androgen production or action varies greatly, depending on the age and sex of the patient. At birth and during infancy, the main problems encountered are cryptorchidism and ambiguous genitalia. During childhood, the two main disorders are precocious puberty in boys and virilisation in girls. In adolescent and adult males, the main clinical problems encountered are due to androgen deficiency. In adolescent and adult women, however, the clinical problems commonly encountered are those associated with androgen excess.
Measurement of total plasma testosterone is currently the most widely used test for assessing androgen status. However, the level of total testosterone, though useful when grossly abnormal, may be unhelpful in patients with mild or moderate abnormality, in whom additional measurements such as SHBG are useful in detecting subtle disturbances. Tests useful in differential diagnosis include plasma levels of gonadotrophins, prolactin, oestrogens, human chorionic gonadotrophin (hCG) and adrenal androgens. Thyroid function tests may be also indicated in problems such as gynaecomastia. It is, therefore, important to emphasise that it is the nature of the clinical problem under consideration which determines the number, type and sequence of endocrine tests.
A careful protocol should be devised to assess androgenic function in each individual case which takes into consideration the nature of the clinical problems, the patient's age and sex. The following comments are presented as guidelines which may assist in the planning of investigations and the interpretation of results.
NEONATAL PERIOD: AMBIGUOUS

GENITALIA
An understanding of the physiology of sexual differentiation makes it possible to suggest the likely anatomical abnormality associated with disorders at various stages of genital development. In genetic male infants, impaired testosterone secretion or action would give defective virilisation in both external and internal genitalia; defective 5 a-reductase activity would give abnormal external genitalia but normal internal ducts, and defective anti-Mullerian hormone would give normal male internal and external genitalia plus fallopian tubes and uterus (often found in an inguinal hernia). I The degree of abnormality depends on the severity of the defect and also on the time at which it becomes manifest; for example, if testosterone secretion is impaired before 12-14 weeks of gestation, hypospadias may occur, whereas if it occurs after differentiation is complete (i.e. > 14 weeks) the only result may be poor genital growth leading to micro-penis. I In genetic females, exposure to androgens at the critical time of development gives rise to normal female internal genitalia but virilised external genitalia. It would appear that very high local testosterone concentrations are required to stabilise the Wolffian ducts and this cannot be achieved in females, even in congenital adrenal hyperplasia. I. 27 The degree of virilisation of the external genitalia is again dependent on the severity of androgen exposures and its timing; if long before the 12th week, a penile urethra may be found whereas if later than 12 weeks only clitoral hypertrophy may be seen. I Gender identity depends on a complex interplay of endogenous factors (e.g. genital appearance, hormonal status) and exogenous factors (e.g. social).2K--311 It is important, therefore, to reach a decision on the sex-rearing of a child with ambiguous genitalia as soon as possible, but only after full investigation and consideration of the future sexual potential. Incorrect sex assignment which has to be changed later in life can be very traumatic. External genital appearance may not be of much help in deciding which pathological process is involved." For example, a female infant with congenital adrenal hyperplasia may present with a very similar external appearance to that of a male with disordered testosterone secretion. 1 Endocrine and cytogenetic investigations are, therefore, necessary for correct diagnosis and to supplement anatomical considerations when deciding sex assignment. I. 31 The cytogenetic tests, screening for X chromatin and karyotyping, give an indication as to the line of investigation, as the aetiological factors are different in males and females. However, it is important to emphasise that a normal karyotype does not exclude the possibility of subtle abnormalities such as mosaicism or translocation. Biochemical investigations should be planned carefully and the nature and sequence of tests are determined by the clinical suspicion and cytogenetic data. 
Congenital adrenal hyperplasia
The commonest cause of ambiguous genitalia in females in CAH; over 90% of such cases are due to 21-hydroxylase deficiency which occurs in up to 1 in 10 000 births." Severe salt loss occurs in approximately 50% of patients with 21-hydroxylase deficiency, usually during the second week of life. 32 However, in premature infants this may occur within the first few days of life. Thus, early diagnosis is essential if the baby is to be treated before a salt-losing crisis occurs.V: 32 Electrolyte measurements are indicated but need to be interpreted in the light of neonatal reference ranges.P Daily weighing of the infant may give a better indication of salt and water loss than serial electrolyte measurements, as the plasma sodium level remains normal until immediately before the crisis. 33 The diagnostic test is plasma 17a-hydroxyprogesterone (17-0HP) measured 48 h or later after birth but before treatment. The timing of the sample is important, as the 17-0HP level is high in normal infants but decreases rapidly during the first two daysY Infants with 21hydroxylase deficiency usually have grossly elevated plasma levels of 17-0HP (more than 10 times the upper limit of norrnalj." and a normal level excludes the diagnosis. Moderately raised levels may be seen in very sick and pre term infants.F': 3h and in II~-hydroxylase deficiency .: ,2 Therefore, serum l l-deoxycortisol (if available) or urine steroid profiles may be necessary to distinguish II B-hydroxylase deficiency from 21-hydroxylase deficiency. 32 Gestational age and stress-related illness must be taken into consideration. 3h If treatment is thought to be necessary before 48 h, it is advisable to obtain a sample for 17-0HP before therapy, but interpretation may be less straightforward. A normal level excludes the diagnosis but an elevated 17-0HP does not necessarily confirm it and in such a case, further investigations such as 17-0HP and cortisol during synacthen stimulation may be required later.
The measurement of the II-oxygenation index (11-01) on a random urine sample has been used to diagnose CAH due to 21-or IĨ -hydroxylase deficiency but it is now superseded by plasma assays and more sophisticated urinary steroid profiles. Reliable information from 11-01 can be obtained only after 8 days of life.:" and values may occasionally be normal for longer periods in cases of II l-l-hydroxylase deficiency.:" Misleading results may also be obtained with some other severe illnesses or with steroid therapy.:" 3 f-l-hydroxysteroid oxidoreductase (dehydrogenase) deficiency is very rare, but if clinically suspected (e.g. severe salt wasting with mild virilisation), diagnosis may be aided by the measurement of serum t;'-steroids, e.g. DHA or their urine matabolites.I" 31 Therapy is monitored by observing the response of the abnormally elevated plasma steroids to glucocorticoid and mineralocorticoid treatment. For 21-hydroxylase deficiency, for example, testosterone, androstenedione or 17-0HP are used to monitor the efficacy of replacement and in assessing androgen status.:" Recent evidence suggests that measurement of androstenedione may have advantages.:" In addition, plasma renin activity may be useful in monitoring mineralocorticoid replacement. 411 . 4 1 When
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monitoring replacement therapy careful consideration should be given to the time of sampling in relation to the last dose, diurnal variation and the stress of venepuncture. 32 Measurements of androstenedione or 17-0HP in saliva or filter paper blood spots show useful potential for monitoring and may become more widely available in the future.V: [42] [43] [44] Viriiisation due to maternal androgens or drug therapy Genetic females exposed to androgens at the critical period of development either from a maternal tumour (which may be hCG dependent) or from androgenic drug therapy, may have normal female internal genitalia but virilised external genitalia. The degree of virilisation is dependent upon the severity of androgen exposure and its timing.
Hermaphroditism
The possibility of abnormal gonadal differentiation should be considered when other conditions (e.g. CAH) have been excluded and when there is discrepancy between cytogenetic, morphological and biochemical findings.:': 45 The presentation of these cases is very variable but the types most likely to present with ambiguous genitalia at birth are mixed gonadal dysgenesis or true hermaphroditism. 31, 4t>-4K The biochemical laboratory has a useful part to play in diagnosis, which rests on basal plasma testosterone levels, morphological and cytogenetic findings. Plasma testosterone is best assayed a few weeks after birth (> 4 weeks) and an hCG stimulation test may be also carried out to evaluate further the Leydig cell function of the testes. A testosterone level in the neonatal male range with a clear and brisk rise following hCG stimulation indicates the presence of testicular Leydig cells even if the chromosomal karyotyping is 46XX and the search for mosaicism and translocation should be intensified.
(ii) Causes of ambiguous genitalia in males-46XY karyotype (a) Impaired testosterone formation Biosynthetic defects. Deficiency of:
Leydig cell hypoplasia (b) Impaired peripheral action 5 a-reductase deficiency Partial androgen insensitivity (c) Hermaphroditism (with mosaicism) (d) Others, e.g. embryological malformation, drugs.
Impaired testosterone formation
In genotypic 46XY males, testosterone and gonadotrophins should be measured. In view of the marked physiological changes occurring in pituitary-gonadal hormones during the neonatal period, careful timing of samples is important for proper interpretation and an hCG stimulation may be necessary to assess further the nature of the gonad. A low basal testosterone with elevated gonadotrophins and a poor response to hCG suggests either Leydig cell hypoplasia or a biosynthetic defect'!: 49 Measurement of a number of plasma steroids including androstenedione, DHA, 17-0HP and progesterone as well as their urine metabolites, are often necessary to define the enzyme block': 50
Impaired peripheral action
A normal basal testosterone with a clear and brisk rise following hCG suggests either 5 a-reductase deficiency or the much more common partial end-organ insensitivity; patients completely insensitive to testosterone are entirely female in external appearance and are thus not usually detected until later in life. 51 Measurement of the plasma testosterone : 5 a-dihydrotestosterone ratio and the ratio of urine S~to 5 a-reduced metabolites may aid in this differential diagnosis.V: 53 remembering that T : S a-DHT ratios are usually lower in infancy.P: 53 Abnormally raised ratios of testosterone : 5 a-dihydrotestosterone have been found in comflete insensitivity and hypothyroidism.s": 5 but the latter should not present a problem in interpretation. Measurement of Sa-reductase activi ty5b-58 and androgen receptorsr!' 59 in genital skin samples provides definitive diagnosis.
Hermaphroditism
This topic has been discussed previously under the 46XX karyotype.
If testosterone response to hCG is normal and impaired peripheral action has been excluded, abnormal gonadal differentiation or embryological malformation or drugs given early in pregnancy, e.g. progestin, should be considered."
INFANCY (i) Micropenis
This has been defined as a normal phenotypic male with a penis whose length is less than 2·5 standard deviations below the mean length for age.:": eo, fll The condition arises from insufficient androgen secretion after 14 weeks' gestation for adequate phallic growth. I The defect may be in th~hYf?thalmus~r pituitary (hypogonadotrophic)," In the testls,fl3 due to partial androgen insensitivity (uncommon), or unknown.P" Patients may present in early life or later on with delayed puberty.
Important investigations include chromosome karyotyping to detect X-polysomes (e.g. Klinefelter's) and other chromosome abnormalities (e.g. Down's, Noonan's or male Turner's syndrome). Before puberty, measurement of plasma testosterone, pre-and post-hCG, is used to assess Leydig cell function, whereas after puberty basal testosterone, oestradiol and gonadotrophins may be sufficient. 31, 6() A full pituitary assessment is usually performed in patients with hypo gonadotrophic varieties, since, except for isolated gonadotrophin deficiency, other pituitary hormones may be deficient as weI1. 31 , 6( ) However, diagnosing gonadotrophin deficiency is very difficult before puberty and may be aided by other clinical findings, e.g. positive family history and poor sense of smell in Kallman's syndrorne": ez (see section on delayed puberty).
(ii) Cryptorchidism
This term relates to an arrest of one or both testes along the normal path of descent.I" 64 The testes usually descend from the abdomen to the scrotum from the 28th week of gestation onwards, and there is good evidence that a functioning pituitary-gonadal axis is necessary. Approximately 3% of male infants have undescended testes but in about 75% of these, the testes have moved into the scrotum by one year.
If the testes are left for a number of years in the abnormal position, spermatogenesis (which is temperature-dependent) and Leydig cell function may become impaired'? and when the testes have not moved into the scrotum by adulthood the risk of malignancy increases.P': 65 Causes: (a) Chromosomal and other congenital abnormalities -(b) Impairment of the pituitary-gonadal axis (c) Idiopathic. Karyotyping may be requested if clinically indicated. Plasma testosterone, before and after hCG, should be measured in patients with no palpable gonads. A rise after hCG indicates the presence of functioning testicular tissue, whereas a lack of response raises the strong possibility ,of anorchia (the vanishing testis syndromej.I': 64 Measurement of basal serum testosterone and LH at 1-3 months may be useful in detecting some of those children whose testes will not descend spontaneously.l": «t in a few of whom testosterone and LH levels are extremely low. In the majority of patients no cause is found.
CHILDHOOD (i) Precocious puberty
Precocious puberty is referred to as isosexual (in accordance with sex phenotype) and complete or true when the secondary sex characteristics and spermatogenesis develop because of activation of the hypothalamic-pituitarygonadal axis (HPGA) at an unusually young age. 23 • 6K Isosexual pseudoprecocious puberty results from gonadotrophins and/or androgen secretion independent of the HPGA. When precocious puberty is primarily due to androgen secretion (i.e. gonadotrophin independent), no spermatogenesis occurs and the testes usually remain small unless a testicular tumour is presenr.P: 69
Causes:
True precocious puberty
Idiopathic; CNS pathology (tumours. congenital abnormalities; hypothyroidism 2. Pseudoprecocious puberty Testicular tumours; adrenal tumours or hyperplasia; hCG-producing tumours and drugs 3. Incomplete precocious puberty-premature adrenarche (pubarche).
Thorough investigation of precocious puberty in boys is usually performed to exclude pseudoprecocious puberty and because a large number of males with true precocious puberty have space-occupying lesions within the CNS. Hormonal investigations are an essential part of this investigation, and include measurement of the levels of plasma testosterone, LH, FSH, 17-0HP, and adrenal androgens plus prolactin, -hCG and AFP in some circumstances. Levels of androgens, gonadotrophins and other hormones within the normal peripubertal limits may suggest idiopathic precocious puberty. The occurrence of hyperprolactinaemia or diabetes insipidus, however, may suggest a hypothalamic lesion.
If increased plasma androgens are found with low LH levels, excess androgen production due to CAH, adrenal or Leydig cell tumour is likely. In the interpretation of the plasma profile of adrenal androgens, it is important to emphasise that although gross elevation strongly suggests adrenocortical tumour, normal or only slightly elevated levels do not exclude it, as predominantly testosteronesecreting adrenocortical tumours can occur. If elevated serum androgens are found with a high LH,~-hCG should also be measured, as the increased LH is likely to be due to crossreaction in the assay by hCG secreted by a gonadal or intra-abdominal tumour (e.g. hepatoblastoma). If hCG does not cross-react in the LH assay, then~-hCG should be measured in any case in which these tumours are suspected. Interpretation of 17-0HP measurement is straightforward, but it is important to point out that the occurrence of a clinically palpable testicular tumour should not preclude the assay of 17-0HP as testicular tumours may occur in patients with CAH. This has been attributed to ACfH stimulation of cells within the testis that morphologically resemble Leydig cells but functionally behave like adrenocortical cells.
(ii) Premature adrenarche As early as 5 years of age, pubic hair, with or without axillary hair, may occur in girls and to a lesser extent in boys. In such cases, the possibility of precocious puberty or pseudoprecocious puberty (tumours) must be considered. However, if all biochemical and radiological investigations are clearly normal the possibility of premature adrenarche should be raised. Precocious adrenarche may not be a reflection of an early onset of complete sexual development (i.e. isosexual precocious puberty). Plasma levels of adrenocortical androgens (DHA, DHA-S and androstenedione) are appropriate to the degree of sexual hair development. Levels of adrenocortical steroids are readily suppressed by dexamethasone administration. The peripheral conversion of adrenal androgens such as DHA and androstenedione to testosterone accounts for the very modest rise in plasma testosterone, which remains at less than 2·5 nmol/L, whilst gonadotrophins remain within the prepubertal range. Monitoring androgen levels periodically will ensure that adrenarche is not the expression of an androgenproducing tumour. 23. 711 (iii) Delayed puberty Puberty in boys may be considered delayed when signs of testicular enlargement do not appear by the age of 15 years of age or SO. 23 The aim of laboratory investigation is to exclude the diagnosis of primary testicular failure by measurement of basal testosterone, LH, FSH and prolactin and the response to an hCG stimulation test. Once primary failure has been excluded, full pituitary function tests may be warranted to exclude secondary (pituitary) or tertiary (hypothalamic) deficiency of gonadotrophins, which may be either isolated or associated with other trophic hormone deficiences.
The endocrine profile in primary hypogonadism is low plasma testosterone with an increase in circulating gonadotrophin levels; stimulation with hCG causes little or no rise in circulating testosterone levels.
Secondary hypogonadotrophic hypogonadism as part of a multiple pituitary hormone deficiency can be diagnosed easily by pituitary function tests (e.g. insulin-induced hypoglycaemia). However, isolated deficiency of gonadotrophins may be difficult to distinguish from the constitutional type of delayed puberty. It has been suggested that a '4-hour' stimulation with gonadotrophin-releasing hormone (Gn-RH) may help to distinguish between the two forms. Patients with hypogonadotrophic hypogonadism exhaust their gonadotrophins with time." 4. ADULTHOOD (i) Impotence It is commonly believed that impotence, i.e. the inability to achieve or maintain penile erection in order to perform penetration and coitus, is rarely of endocrine origin and that more than 90% of patients have an exclusively psychogenic cause. Erectile potency, however, is a complex integrated process which requires, in addition to a healthy psyche, a functionally intact vascular, neurological and endocrine system. Therefore, evaluation of these various factors must be carried out before the diagnosis of psychogenic impotence is made. [72] [73] [74] Causes. Drugs; neurological, e.g. spinal cord lesions (especially lumbosacral); vascular, e.g. conditions affecting penile blood supply; systemic illness; endocrine disease; psychogenic.
Biochemical investigations. The role of the biochemistry laboratory is mainly in the investigation of systemic illness and endocrine disease as causes of impotence. It is important to have a full drug history as many drugs are associated with decreased potency. [74] [75] [76] Such drugs include CNS depressants (e.g. phenothiazines, benzodiazepines), antidepressants (e.g. tricyclic compounds and monoamine oxidase inhibitors), antihypertensives (e.g. methyldopa, clonidine), some diuretics (e.g. spironolactone), oestrogens and antiandrogens.
Almost any acute or severe chronic systemic illness may affect potency and investigation of liver and renal function and screening tests for diabetes mellitus may be needed. From the endocrine point of view, tests initially indicated are plasma levels of testosterone, LH, FSH and prolactin, and possibly thyroid function tests (TFTs). Abnormalities that may be found occasionally include hyperprolactinaernia" due to pituitary tumour or hypothalamic lesion (stress and drug effects having been excluded), hyper-or hypogonadotrophic hypogonadism, rarely occult hyperthyroidism (in these cases total plasma testosterone may be very high due to the marked increase in SHBG but the free testosterone is low) and hypothyroidism. Sometimes, adrenocortical insufficiency or excess may be suggested clinically, both or which may impair potency, and require investigation.
(ii) Gynaecomastia Gynaecomastia is excess glandular enlargement of the mammary gland in males. Mild and transient gynaecomastia is common in the neonate and probably results from the action of placental oestrogens. It is also common at puberty, occurring in approximately half of normal boys, and seems due to a temporary imbalance of oestrogen/androgen production. 78 . 79 Gynaecomastia may also be seen in old age and obesity for the same reason, but clinicians may often wish to exclude pathological causes in this group. Thus they may wish to investigate gynaecomastia occurring at any time outside the neonatal/pubertal period and even in peri pubertal boys if it persists for a tong time The number of causes is very large. Therefore, only a few general comments will be made and the reader is referred to further, more detailed, references. HII. HI The clinical finding of gynaecomastia with ambiguous genitalia may raise the suspicion of a defect in androgen action, e.g. partial androgen insensitivity, or possibly true hermaphroditism, especially if associated with cyclical haematuria. On the other hand, Klinefelter's syndrome may be suspected. In these situations, karyotyping is necessary. Another rare cause of genital ambiguity with the development of gynaecomastia at puberty is partial 313-hydroxysteroid oxidoreductase deficiency. H2 Male patients with 17 l3-hydroxysteroid oxidoreductase deficiency are
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also very rare but usually have unambiguous female external genitalia. They are raised as girls but virilise at puberty with about 50% developing breasts. J. H3 In patients presenting with gynaecomastia alone the finding of raised plasma LH with low or normal testosterone may suggest gonadal insufficiency or possibly an hCG-secreting tumour, if hCG cross-reacts in the LH assay.HI Low plasma LH and low or normal testosterone, associated with grossly raised oestriol, may suggest an oestrogen-secreting tumour. HII Finding raised LH, testosterone and oestradiol suggests partial androgen resistance, with genital ambiguity or isolated gynaecomastia, or an hCG-producing tumour. 84 A marked increase in adrenal androgens suggests the possibility of a rare feminising adrenal tumour.
In patients with hyperthyroidism, high testosterone and SHBG are usually found which leads to decreased free testosterone. III In hypothyroidism, hyperprolactinaemia plus alteration in steroid metabolism may be the cause. Persistently elevated and very high prolactin levels suggest the possibility of a prolactinoma but gynaecomastia is not a common presentation in these patients.i" (iii) lnfertility/subfertility Infertility is a common problem and is estimated to occur in at least 10% of couples.": H5 An abnormality in the male is as important as in the female and should be investigated in every case. Fertility in the male depends upon normal spermatogenesis and the status of the seminal tract and fluid. From the endocrine point of view, both FSH and androgens are required for full spermatogenesis.
Causes:
1. Primary testicular disorders-genetic and developmental 2. Acquired testicular disorders---drugs, chemical and physical agents, infections, immunological, trauma 3. Obstruction or damage to outflow tractscongenital or post inflammatory (e.g. cystic fibrosis) 4. Systemic disease---e.g. cirrhosis, renal failure, dystrophia myotonica 5. Hypothalamic or pituitary disease 6. Idiopathic.
The idiopathic group is the largest and biochemical investigations are essentially, therefore, tests of excl usion.
Laboratory investigations. It is important to know any drugs that the patient is taking as spermatogenesis may be inhibited by a number of compounds including cytotoxics, antimalarials, monoamine oxidase inhibitors, nitrofurantoin, and sulphasalazine.P: 76 Semen analysis is required and chromosomal analysis and testicular biopsy when indicated. Between 5 and 10% of infertile men have abnormal karyotypes and these patients usually have severe oligospermia (sperm density <1 million per mL) or complete azoospermia. A large number of systemic diseases can cause infertility which may be reversible. Seminal tract obstruction may also be corrected surgically in some cases.
Endocrine investigations. The endocrine tests indicated are FSH, LH, testosterone, prolactin and possibly 17-0HP. Dynamic tests such as Gn-RH have been used but the results appear to have limited or no value over the basal investigations. M6 The single most important diagnostic endocrine test is basal FSH M6 • M7 and this should be interpreted in relation to the sperm density. Basal FSH tends to rise and exceed the normal range only when sperm density falls below 1-2 million per mL. A normal endocrine profile may be found with sperm densities > 1·0 million per mL and are usual and thus unhelpful when sperm density is > 5 million per mL. M A normal serum FSH and testosterone in a consistently azoospermic patient is diagnostic of obstruction in the duct system which may be treatable. Patients with germ cell aplasia in some or all of the seminiferous tubules tend to have modestly elevated FSH levels but normal testosterone. Also, patients with hypospermatogenesis or germ cell arrest may have normal or only slightly raised FSH levels with a normal testosterone.
Levels of testosterone and LH are likely to be abnormal in infertile men with primary or secondary hypogonadism. In most cases, the hypogonadism is clinically apparent. However, in some patients with secondary causes, overt clinical symptoms of hypogonadism may not be apparent despite 'very low plasma testosterone, gonadotrophins, thyroxine and cortisol levels. Finding a markedly elevated serum testosterone (i.e. > 35 nmol/L) should raise the possibility of occult hyperthyroidism and TITs should be performed, III but routine thyroid screening of all patients is of dubious value. MM Raised testosterone levels with consistently elevated LH suggests end-organ insensitivity to an-drogens which may be limited to only a few target organs. M'i. 'i0 In these cases, FSH is usually but not always elevated as well.
Measurement of prolactin may be relevant to the interpretation of testosterone and LH results in infertile men. Hyperprolactinaemia, which is rare in men, may cause a functional suppression of testosterone, LH and FSH concentrations (thus LH and FSH are often maintained within normal Iimits).77 Further investigations are necessary to elucidate the cause of raised prolactin levels. Subsequent suppression of prolactin may result in a rise in the levels of testosterone, LH and FSH.
Finally, it has recently been suggested that 17-0HP measurements may be useful in detecting a small group of oligospermic patients who appear to have 11~or 21-hydroxylase deficiency leading to overproduction of DHA-S and 17-0HP. MM . 'il Treatment with glucocorticoids appears to improve fertility in this group which thus represents a potentially treatable cause of male infertility.f" 'il Others, however, have not found measurement of basal l7-0HP to be very rewarding.Y'
(iv) Hirsutism-acne, with or without menstrual irregularity
The skin is a major target organ for androgens'" and the hair follicles in areas of secondary sexual hair growth in males and females are androgen dependent. The activity of 5a-reductase with local production of 5a-DHT in these areas appears to be an important factor in stimulating hair growth.?" The sebaceous gland is another target tissue and excessive sebum secretion (seborrhoea) is a manifestation of androgen stimulation which is a prerequisite for the development of acne in females." Hirsutism (i.e. excessive growth of androgendependent sexual hair in a male patternj'": 'if> has a wide spectrum of severity'i5-'i 7 and must be judged against the cultural and genetic background. 'iM It is a common problem which is imperfectly understood at present; for example, hirsutism may be due to excessive androgen stimulation or possibly to an increased sensitivity to androgens. Sa-reductase activity has been shown to be increased in skin hornogenates and skin fibroblasts of hirsute patients,lJ'J-1ll1 but this may reflect stimulation by subtle increases in free androgen. 1112. 1113 Intracellular androgenreceptor-binding capacity has recently been shown to be the same in hirsute and in normal wornen.l'" Thus, it is not clear if there is an inherent increased sensitivity to androgens In some hirsute patients.
Causes:
1. Drugs-anabolic steroids, androgens, danazol 2. Ovarian-tumours, polycystic ovarian syndrome (PCOS) 3. Adrenal-partial or late-onset congenital adrenal hyperplasia, tumours, Cushing's syndrome 4. Idiopathic.
Investigations. Some drugs such as anabolic steroids or danazol may cause hirsutism but others such as phenytoin, diazoxide and minoxidil may give rise to excess vellus hairhypertrichosis. 1114 Such causes must be excluded before proceeding to biochemical investigations. If suspected, Cushing's syndrome should be investigated at the outset either by measuring plasma cortisol after I mg overnight dexamethasone suppression or by estimation of 24-hour urinary free cortisol.
The tests initially indicated are basal testosterone, LH, FSH and prolactin. Further t,ests which may be required are circulating adrenal androgens, SHBG and 17-0HP (after ACTH stimulation).
A marked elevation of plasma testosterone (e.g. more than twice the upper limit of normal) must raise the possibility of an androgenproducing tumour. III~Measurement of adrenal androgens is helpful in the diagnosis of an adrenal tumour (see discussion of tumours with androgen manifestations). Testosteronesecreting ovarian tumours usually produce very high plasma testosterone levels with normal or modestly raised levels of adrenal androgens; similar patterns may be seen occasionally with adrenal tumour and rarely in peos. Patients with PCOS exhibit signs of mild to moderate androgen excess; 11If>. 1117 a disproportionately elevated concentration of plasma LH in relation to FSH is commonly found. In young patients at an early stage of peos, basal LH levels may not be clearly raised but the LH response to Gn-RH will be exaggerated. Hyperprolactinaemia is found in some cases, and may be the only gross abnormality in the biochemical screen. III~The finding of unexplained, persistently elevated serum prolactin (causes such as hypothyroidism, drugs and stress having been excluded) may be aetiologically important since an increase in adrenal androgen production appears to occur in hyperprolactinaemic women. I(~) The possibility of pituitary adenoma in these patients should be considered.
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Partial deficiencies in the enzymes of steroid biosynthesis are present in a few patients who present with hirsutism and menstrual irregularity (partial congenital adrenal hyperplasia) but who are often clinically indistinguishable from patients with idiopathic hirsutism or PCOS. H2 . 1111-113 Levels of the relevant plasma androgen (e.g. 17-0HP in 21-hydroxylase deficiency) or urine metabolites may be abnormal. However, these measurements are usually within normal limits and diagnosis requires dynamic tests such as ACTH stimulation. 1m In the majority of patients with hirsutism/ acne and in whom tumours, Cushing's syndrome, PCOS, etc., have been excluded, plasma testosterone concentrations are only modestly elevated or fall within normal limits. Multiple sampling!": 115 or assessing free testosterone concentrations 11f>. 117 increases the number with detectable abnormalities. Many of these patients with so-called 'idiopathic' hirsutism may be demonstrated to have subtle abnormalities, of ovarian and/or adrenal function, on detailed investigation. I I X--1211 The measurement of free testosterone is difficult but some workers have found that a derived free testosterone concentration or an androgen index, derived from the simpler measurements of SHBG and testosterone, are useful indicators of abnormal androgen statusYI. 122 It is doubtful if these further investigations contribute substantially to patient management and in the present financial climate they are probably not justified.
(v) Tumours
Virilising tumours in females are most commonly ovarian in origin but they may also arise from the adrenal cortex. There may be difficulty in distinguishing between these two sites of origin in some patients. The most useful biochemical tests when tumours are suspected are plasma levels of testosterone and plasma or urine adrenal androgens. Ovarian tumours tend to present with markedly elevated testosterone (usually > 5·0 nrnol/L) but normal or only slightly raised adrenal androgens. On the other hand, the biochemical profile in the majority of virilising adrenal tumours tends to show a moderately raised serum testosterone level (usually <5·0 nrnol/L) associated with grossly raised adrenal androgens. However, there are exceptions and a number of virilising adrenal tumours have been documented in which the major androgen produced was testosterone. The biochemical profile in such cases was similar to those of ovarian rather than adrenal tumours,IB-127 and some of these patients had had ovariectomy performed before the correct diagnosis was made.
In a recent review of 34 cases of adrenal tumours,213 nine have been reported to be testosterone producers. In each of these, the site of testosterone production was presumed to be the ovary since adrenal androgen levels were normal. Eight of these nine patients had their ovaries resected before correct identification of the adrenal gland as the source of testosterone production. Such adrenal tumours may be small and not easily detected even by CT scanning. Dynamic tests may be attempted to locate the type of the tumour and it is often assumed that suppression by dexamethasone or stimulation by ACTH suggests an adrenal source, while oestrogen suppresion or LHJhCG stimulation indicates an ovarian source. These tests lack specificity, as dexamethasone may suppress ovarian tumours while ACTH may stimulate an ovarian (or testicular) tumour. Adrenal tumours may also respond to LHJhCG stimulation and the secretory activity of such tumours may be markedly enhanced if the patient becomes pregnant or enters the menopause. 121<--130 The LHJhCG responsive adrenal tumours mostly described in post-menopausal women possess LH receptors, lJO although their embryological origin is uncertain. The pattern of steroidogenesis and the histology seen in many virilising adrenal adenomas which responded to hCG stimulation was similar to that of luteinised stromal cells seen in some ovaries. Similarly, Leydig-type cells have been observed in the normal adrenal cortex and also in a virilising adrenal adenoma. 131 Thus, dynamic tests cannot be relied upon to distinguish conclusively between ovarian and adrenal tumours.
Measurement of adrenal androgens in plasma or urine is generally helpful in identifying the type of virilising tumour in females. It is usually safe to assume that the tumour is adrenal in origin if the testosterone level is modestly raised and is associated with grossly elevated adrenal androgens. Interpretation of markedly raised testosterone in women with normal or slightly raised adrenal androgens needs caution. Abdominal CT scan to search for an adrenal mass as well as an ovarian tumour may be necessary but some tumours may be small and not easily detected. Should the CT scan prove equivocal, venous chatheterisation can be used to look for a gradient in levels of testosterone and other androgens.
In men, testicular tumours (seminoma and non-seminoma) tend to cause slight impairment in Leydig cell function of the contralateral testis. In most such patients, the testosterone level is normal or subnormal, with normal or raised gonadotrophin levels. IJ2-1J5 Treatment (radio-and/or chemotherapy) results in azoospermia with further rise in FSH values, but the testosterone and LH levels remain stable.P" The FSH value tends to remain elevated subsequently for several years, as recovery of spermatogenesis in these patients may be protracted.
Patients with CAH and Cushing's disease may develop testicular tumours. IJ5 This has been attributed to ACTH stimulation of cells in the testicles which morphologically resemble Leydig cells but behave functionally like adrenocortical cells. These cells exhibit 11~ hydroxylase activity and synthesise cortisol in vivo. The occurrence of these tumours in patients with CAH is probably not uncommon but their origin is not known.
(vi) Systemic conditions affecting androgens
Serum testosterone decreases temporarily in response to many severe stress situations such as after surgery, lJ/>-13K respiratory failure lJ9 and even after severe unaccustomed exercise.i'" This may be related to ACTH or cortisol secretion. [141] [142] [143] The following brief comments are related to conditions which are associated with androgen disorders.
(a) Nutritional disturbances
Obesity: Obesity in men has been associated for a long time with decreased libido and impotence and a number of studies into the HPGA axis have been performed. 144. 145 When body weight exceeds ideal body weight (IBW) by 160% then the plasma testosterone level tends to be low-normal or subnormal. This is not associated with clinical evidence of hypogonadism, because SHBG levels also decrease so that the free testosterone concentration remains relatively normal. 146 In massively obese men (250% IBW), plasma testosterone falls well below normal and SHBG falls further but not sufficiently to prevent a decrease in.free testosterone.l'" Plasma LH, FSH and prolactin concentrations are normal as are responses to hCG and Gn-RH. Concentrations of plasma oestradiol (total and free) and oestrogens are elevated probably due to the conversion of androgens in adipose tissue, but do not lead to feminisation. Thus, in the massively obese, total and free testosterone concentrations are decreased, gonadotrophins are normal and oestrogens are increased and a mild state of hypogonadism may exist associated with impotence, decreased libido, decreased facial hair, etc. 14 1>--14K The cause of the decrease in SHBG in obese males is not known.
In contrast to the situation in men, plasma testosterone .in massively obese women is elevated while SHBG is decreased, which leads to an increase in free testosterone.J'" Adrenal androgens and urine 17-oxosteroids are also elevated, possibly as a by-product of cortisol hypersecretion. 144. 145 These findings may be causally related to the increased incidence of amenorrhoea and hirsutism in female obesity. All of these findings are reversible with substantial weight loss. 150, 151 Gonadotrophins and their response to Gn-RH have been found to be normal before and after weight loss.
Undernutrition: This may also lead to disturbances in gonadal function, the most dramatic example being anorexia nervosa. This condition is rare in men but when it occurs, low plasma concentrations of testosterone and gonadotrophins are found during the acute phase. 152 Weight gain is associated with gonadotrophins returning to normal levels but that of testosterone may remain low to low-normal for a considerable time. 153 Despite these findings, sexual function appears to be normal.
In women, however, in whom anorexia nervosa is associated with amenorrhoea and severe disturbances of the HPGA axis, plasma testosterone (and oestradiol) levels may be higher than in normal women. 154 Weight gain produces a reversal of these abnormalities.
Renal failure: In men with chronic renal failure, decreased libido and potency is common and infertility may also be present. Plasma testosterone concentrations may be normal or decreased but LH is often increased 155~157 and these changes are correlated with the degree of renal failure. There appears to be diminished gonadal sensitivity to LH as decreased testosterone responses to hCG have been found. 156, 157 The plasma FSH level is usually normal but may be raised with severely impaired spermatogenesis.P" Mild hyperprolactinaemia is also often seen. 15K. 159 These changes may reverse with transplantation but are not affected by dialysis. 15 K-160 Alcohol and liver disease: Chronic alcoholic men, with or without evidence of liver disease, often have evidence of hypogonadism with oligo-or azoospermia and sometimes oestro-genisation with gynaecomastia.P'': 161. 162 Plama testosterone levels are often low, and SHBG and LH increased. Alcohol toxicity may affect not only the testis but also the hypothalamus and pituitary.l?': 162 Recovery of sexual function may occur in some but not all patients after a long period of abstinence.I'f Coeliac disease: A number of male adults with coeliac disease may have" infertility or hypogonadism. In these patients an unusual endocrine profile may be found. 163. 164 This is an increase in total plasma testosterone to supranormal levels, an increase in SHBG, and an actual increase in free testosterone. There is also an increase in plasma LH concentration suggesting resistance to testosterone action. An interesting finding is a decrease in serum 5 a-DHT, which suggests an impairment of 5 a-reductase activity. These findings seem related to the coeliac disease process as they are not found in Crohn's disease and they revert to normal as the jejunal mucosa returns to normal.
Contraception: Vasectomy is becoming a more common method of fertility control. Studies undertaken to assess the effect on Leydig cell function have shown that plasma testosterone and LH levels remain essentially unchanged with no evidence of significant alteration in testicular endocrine function.l'?
BIOCHEMICAL MONITORING OF TESTOSTERONE REPLACEMENT THERAPY
There are a number of different therapies available.I": 166. 167 Those commonly used include:
1. Intramuscular injection of long-acting esters (e.g. testosterone enanthate) or ester mixtures (e.g. Sustanon) 2. Subcutaneous implants of fused testosterone crystals 3. Sublingual testosterone 4. Oral preparations (testosterone undecanoate, methyl testosterone).
Although the effectiveness of treatment is monitored clinically, plasma testosterone measurements may be useful in optimising therapy especially when the clinical effect is less than expected. It is generally assumed that the ester bond is initially cleaved, and that measurement of testosterone level in a treated patient reflects the actual hormone concentration. Current reports, however, appear to contradict the above assumption since large amounts of unhydrolysed esters are present in the serum. 16M Furthermore, the steroid moiety may undergo metabolic alterations prior to the cleavage of the ester bond, e.g. dihydrotestosterone ester. Finally, these esters may crossreact in various RIA systems, especially direct assay procedures. It is, therefore, important to emphasise that the accuracy of plasma testosterone measurements in treated patients may be dependent both on the procedure (e.g. extraction step) as well as the specificity of antibody. If the specificity of the method has been validated against the preparation in use, then interpretation of the measured concentration is dependent on the time of sampling in relation to the last dose. With long-acting testosterone ester injections, supraphysiological peak concentrations occur at 24-48 h which decline to subnormal levels by 2-3 weeks depending on the dose. 1M. 167. 169 Monitoring may be carried out best midway between injections (the testosterone concentration should be in the middle of the reference range), 167 or just before the next injection. 1M Fused testosterone implants give peak serum testosterone levels around the upper limit of the reference range between 2 and 10 weeks which fall to the lower limit at around 16-18 weeks. 16M Testosterone undecanoate is given orally twice daily; serum testosterone levels peak approximately 4 h post-dose and should faB to the lower limit of the reference by 8-10 h. I66 . 169 The adequacy of therapy in patients with primary hypogonadism may be assessed further by measuring LH a few months after starting therapy and demonstrating suppression to within the reference range. 167
DYNAMIC TESTS (i) hCG stimulation test
The hCG stimulation test is commonly used for assessing Leydig cell function (hypogonadism) in neonates, children and adults. There is, however, no agreement in the literature regarding the optimum protocol, namely the mode of injection (i.m. or i.v.), the amount injected and its timing; nor is there agreement regarding the time of blood sampling for assessing the response.
It is important to highlight certain factors regarding the mode of action of hCG. The testosterone response to a single hCG injection is biphasic. During the first 2 to 4 h following hCG administration there is an acute increase in testosterone output which probably reflects the secretion of stored steroid. Levels then fall 171J before gradually rising to reach another maximum (plateau) between 2 and 4 days after hCG injection. This second increase reflects the synthetic ability of the testes to produce and secrete steroids. 171 The initial increase in testosterone levels is approximately 1·5-fold in adults, irrespective of the mode of hCG administration. The second major rise is two-to four-fold in adults and again is essentially the same whether hCG is given i.v. or i.m. A second dose of hCG may be ineffective in stimulating further testosterone secretion if it is given 72 h or less after the first hCG injection. It has been clearly shown that almost equal increases in testosterone levels occur in response to a single injection, or hCG injections repeated on three successive days, in normal men, patients with gonadotrophin deficiency and in boys with delayed puberty.!" It seems, therefore, clear that protocols which include a multiple daily hCG injection are inconvenient and wasteful.
As a dynamic test hCG may be given ideally at intervals of 3 to 4 days. For the purpose of treatment, however, a weekly injection would maintain adequate serum testosterone levels since hCG has a component with a long half-life which ensures ade~uate Leydig cell stimulation over this period. I 2 The dose of hCG which produces maximum stimulation appears to be in the order of 25-50 IU/kg body weight given i.m, Higher doses are of little or no value in stimulating further Leydig cell function.
The action of hCG in stimulating other testicular steroids such as 17-hydroxyprogesterone and oestradiol is age dependent, and the steroidogenic response in prepubertal boys and mature men is fundamentally different. The most essential feature is the absence of responses of serum 17-0HP and oestradiol in prepubertal boys, despite a clear and sharp rise in testosterone. In adult men, the relatively modest rise in testosterone is associated with an increase in 17-0HP and oestradiol. It appears that Leydig cell sensitivity to hCG and resultant testosterone secretion decreases with the appearance of its oestradiol and 17hydroxyprogesterone response. The increased intra-testicular oestradiol appears to inhibit testicular C17-20 lyase and to a lesser extent 17-hydroxylase activity.17~175 Thus it seems that the acquisition of oestradiol synthesising capacity is an essential part of prepubertal Leydig cell maturation.
An hCG test consistmg of at least two intramuscular injections of 50 IU/kg body weight, administered at intervals of 3-4 days, would provide a maximum degree of Leydig cell stimulation. The number of injections should be related to the type of clinical problem under consideration, e.g. prolonged stimulation is essential to confirm anorchia, while shortterm stimulation would be acceptable in excluding a 1 0 testicular disorder in patients presenting with infertility or impotence. Blood sampling should be carried out before testing and at 72 h after each injection (i.e. just before the next injection in multiple stimulations) if only testosterone is to be measured. However, if other related steroids such as 17-0HP, oestradiol, etc., are also to be measured together with testosterone, as in cases suspected of congenital deficiency of some testicular enzymes (e .g. pseudohermaphroditism) then sampling should be made at 48 h rather than at 72 h after the injection since testicular steroids such as 17-OHP and oestradiol tend to peak 24 h before testosterone, 171. 174 levels of which are. however, still close to maximum. An earlier sampling would, therefore, reflect more adequately the overall steroidogenic pattern of the testes under the influence of hCG stimulation.
From the age of 6 months of life onwards, the testicular response as estimated by the rise in testosterone levels after prolonged stimulation (five or more injections) does not vary with age. The range of absolute rise (i.e. post-hCG from basal) is from 10 to 35 nrnol/L. The maximum increment in the response of testosterone is approximately 70-fold in prepubertal boys. 6-fold at early puberty, and 2--4 fold in adults. [174] [175] [176] hCG stimulation has little or no value in assessing ovarian steroid production in women. The response to heG in women with normal sized ovaries tends to be small and variable but a greater rise may be seen in patients with diseased ovaries such as the polycystic ovarian syndrome.
(ii) Adrenocorticotrophic hormone (ACTH) Serum testosterone is undoubtedly affected by pharmacological doses of ACTH in normal men and women. ACTH administration reduces testosterone in normal men 142 whereas in normal women a rise of approximately 50% is commonly seen. 177. 17~Although ACTH is rarely used as a dynamic test for assessing androgenic status it is important that such changes should be kept in mind when evaluat-
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ing the indications for ACTH as a therapeutic agent.
(iii) Gonadotrophin-releasing hormone stimulation test (Gn-RH stimulation test)
A single Gn-RH test cannot differentiate between hypothalamic and pituitary causes of hypogonadism. 179 . IXO A normal response does not exclude pathology, but a diminished response may indicate a hypothalamic or pituitary disease requiring further investigations. Repeated stimulation with Gn-RH may enable distinction between pituitary and hypothalamic disorders when there is a poor initial response to Gn-RH. Patients with hypothalamic hypogonadism have been reported to have a normal response to Gn-RH when tested immediately after Gn-RH 'priming'. IX!. IX2 A Gn-RH test is not reliable in distinguishing gonadotrophin deficiency from constitutional delayed puberty.74. IX3 However, a 4-hour stimulation with Gn-RH may prove useful in this respect as patients with gonadotrophin deficiency appear to lose their responsiveness with time (see section on Delayed Puberty).
(iv) Clomiphene stimulation test
Clomiphene is a synthetic non-steroid compound which binds to hypothalamic steroid receptors blocking the feedback of gonadal steroids. This leads to increased Gn-RH release which stimulates LH and FSH secretion when the hypothalamic-pituitary unit is intact. Diminished or absent responses may be seen with both hypothalamic and pituitary disease. Thus, this test IX3 adds little useful information over and above that given by basal LH and FSH measurements. 184 The clomiphene test may be of limited value in assessing delayed puberty. A definite response suggests that puberty is advancing and that full sexual development will oCCUr. IX3 However, this response is only seen when testosterone levels of around 3·5 nmoIlL are attained l X5 equivalent to puberty stage 2 to 3.21 Therefore, it is of no use before this time or in distinguishing prepubertal delayed puberty from gonadotrophin deficiency.
DRUGS AFFECTING THE
INTERPRETATION OF BLOOD TESTOSTERONE CONCENTRATIONS
Oestrogens
Diethylstilboestrol: This oestrogen is commonly used in men in the treatment of androgen-dependent prostatic cancers; it reduces blood testosterone levels into the normal female range.l'" SHBG rises, thereby further decreasing free testosterone.
Oestrogen in oral contraceptives and during pregnancy causes up to 3-fold increase in testosterone concentrations due to increase in SHBG.
Danazol: Used in the treatment of endometriosis; causes a 20% fall in SHBG and displaces testosterone from it. The increase in free testosterone can be up to 90%. IM7-IMC yproterone acetate: Is an anti-androgen used in the treatment of male hypersexuality and precocious puberty in girls and boys and sometimes in hirsutism. It suppresses plasma testosterone in adult men but not in children with precocious pubertyl9U. I'll and decreases testosterone in hirsute women.'!"
Thyroid hormone: The increase in SHBG in thyrotoxicosis results in a 2 to 3-fold increase in testosterone levels. [192] [193] [194] These effects are reversed in hypothyroidism.
Dopamine antagonists: Bromocriptine causes an increase of about 20% in testosterone with no concurrent change in LH levels. Dopamine antagonists such as metoclopramide generally cause decrease in testosterone although sulpiride and pimozide which increase the prolactin levels have no effect on serum testosterone. [195] [196] [197] Anti-psychotic drugs: Thioridazine causes slight suppression in testosterone in patients on long-term therapy. Other neuroleptic agents such as haloperidol and pimozide do not alter testosterone levels . 198 Spironolactone: The anti-androgenic properties are caused by displacing DHT from its cytosol receptors. It also decreases plasma testosterone levels. 199. 20U Histamine H 2 receptor antagonists: Cimetidine has anti-androgenic properties because it displaces DHT from its binding sites at hypothalamic and pituitary levels.i'" and causes up to 20% increase in testosterone levels on chronic administration. 202 Ranitidine, a more powerful histamine H 2 receptor antagonist, has no anti-androgenic activity. 203, 21)4 Anti-epileptics: Carbamazepine, phenytoin, primidone and sodium valproate cause reduction in free testosterone concentration; usually no change in total testosterone,205-20M but a small rise may occur.
Antibiotics: Tetracycline reduces both total and free testosterone by about 10-20% but has no effect on SHBG concentration.F'" Rifampicin: Causes an increase in testosterone probably due to increase in microsomal activity and increased biosynthesis.i'" Cytotoxics: Cyclophosphamide causes a decrease in testosterone due to testicular atrophy.I!'
